Bantam Pharmaceutical is a privately held biotechnology company focused on the discovery and development of innovative cancer therapeutics.

Bantam has implemented a novel chemical biology platform to discover and develop drugs that modulate a nexus of critical cancer vulnerabilities essential for cancer development and growth. Our current lead program is rapidly advancing toward clinical trials.

Founded 2015

Raised $9MM to date


Over 150 years of drug discovery & development experience from target identification to launch

Core Platform

Chemical biology approach using high content cell imaging for phenotypic screening and selection of potent modulators of cell transformation


Development Stage

Seeking Partnerships & Investments to progress program through      proof of concept

Targeting Key Cancer Hallmarks for the Development of Novel Cancer Therapeutics

The mechanism of action for Bantam’s compounds is centered around cell cycle control at the G0/G1 interface with profound effects on cancer cell metabolism and the synthesis of cancer promoting proteins.

Currently advancing towards clinical trials with the plans to generate POC in diffuse large B-cell lymphoma and further indication development in colorectal cancer.

Interested in contacting Bantam regarding further information?